AVEX Stock Analysis: AEVEX | NYSE
Aerospace & Defense | NYSE, USA | Market Cap: 839m USD | 12M Return: -31.2% | US00835T1079 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.2M
Warnings
Tailwinds
Seasonality 0.6 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
AEVEX Corp. is a U.S. defense technology contractor focused on unmanned aerial systems (UAS) and related mission capabilities. Founded in 2020 and headquartered in Solana Beach, California, the company supports the U.S. militarys push to expand its portfolio of autonomous and attritable aerial platforms, a priority reinforced by the Department of Defenses Replicator Initiative introduced in 2023 to accelerate fielding of large quantities of low-cost autonomous systems.
The business is organized into two segments. The Tactical Systems segment designs and manufactures autonomous, modular unmanned systems, including UAS and unmanned surface vehicles (USVs), intended to be expendable or low-cost-per-unit (attritable). The Global Solutions segment delivers bespoke mission services such as AI-enabled airborne intelligence, surveillance, and reconnaissance (ISR), counter-UAS (C-UAS) support, additive manufacturing, and specialized aircraft engineering, modification, and testing. As a small-cap firm, AEVEX typically competes in niche or classified contracting lanes, often as a subcontractor or specialized vendor to larger defense primes.
- DoD unmanned systems spending accelerates under UAS dominance strategy
- Counter-UAS and ISR demand surge amid global drone threats
- Competition intensifies from Anduril and Kratos in attritable UAS market
| Net Income: 45.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -12.96 > 1.0 |
| NWC/Revenue: 50.97% < 20% (prev 15.51%; Δ 35.46% < -1%) |
| CFO/TA -0.02 > 3% & CFO -19.2m > Net Income 45.5m |
| Net Debt (-98.2m) to EBITDA (94.2m): -1.04 < 3 |
| Current Ratio: 5.66 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (88.5m) vs prev 83.13% < -2% |
| Gross Margin: 24.19% > 18% (prev 28.12%; Δ -3.93% > 0.5%) |
| Asset Turnover: 92.64% > 50% (prev 70.46%; Δ 22.19% > 0%) |
| Interest Coverage Ratio: 2.66 > 6 (EBIT TTM 72.7m / Interest Expense TTM 27.3m) |
| A: 0.37 (Total Current Assets 431.4m - Total Current Liabilities 76.2m) / Total Assets 948.1m |
| B: -0.56 (Retained Earnings -533.7m / Total Assets 948.1m) |
| C: 0.10 (EBIT TTM 72.7m / Avg Total Assets 752.4m) |
| D: -1.94 (Book Value of Equity -533.7m / Total Liabilities 274.6m) |
| Altman-Z'' = -0.77 = CCC |
| DSRI: 3.0 (Receivables 188.6m/24.0m, Revenue 697.0m/392.2m) |
| GMI: 1.16 (GM 28.12% / 24.19%) |
| AQI: 0.67 (AQ_t 0.51 / AQ_t-1 0.76) |
| SGI: 1.78 (Revenue 697.0m / 392.2m) |
| TATA: 0.07 (NI 45.5m - CFO -19.2m) / TA 948.1m) |
| Beneish M = -0.86 (Cap -4..+1) = D |
As of November 13, 2026, the stock is trading at USD 13.76 with a total of 5,941,280 shares traded. Over the past week, the price has changed by +48.60%, over one month by -4.18%, over three months by -39.52% and over the past year by -31.20%.
Current recommended Stop Loss: 12.00 (which is 12.8% or 1.4 ATR below the current price).
AEVEX has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy AVEX.
- StrongBuy: 6
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 25.8 | 87.5% |
P/E Trailing = 57.7619
P/E Forward = 16.6945
P/S = 1.2042
P/B = 5.9047
Revenue TTM = 697.0m USD
EBIT TTM = 72.7m USD
EBITDA TTM = 94.2m USD
Long Term Debt = 96.6m USD (from longTermDebt, last quarter)
Short Term Debt = 5.65m USD (from shortTermDebt, last quarter)
Debt = 117.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.99m
Net Debt = -98.2m USD (calculated: Debt 117.1m - CCE 215.2m)
Enterprise Value = 741.2m USD (839.4m + Debt 117.1m - CCE 215.2m)
Interest Coverage Ratio = 2.66 (Ebit TTM 72.7m / Interest Expense TTM 27.3m)
EV/FCF = -27.74x (Enterprise Value 741.2m / FCF TTM -26.7m)
FCF Yield = -3.60% (FCF TTM -26.7m / Enterprise Value 741.2m)
FCF Margin = -3.83% (FCF TTM -26.7m / Revenue TTM 697.0m)
Net Margin = 6.53% (Net Income TTM 45.5m / Revenue TTM 697.0m)
Gross Margin = 24.19% ((Revenue TTM 697.0m - Cost of Revenue TTM 528.4m) / Revenue TTM)
Gross Margin QoQ = 23.61% (prev 26.07%)
Tobins Q-Ratio = 0.78 (Enterprise Value 741.2m / Total Assets 948.1m)
Interest Expense / Debt = 23.32% (Interest Expense 27.3m / Debt 117.1m)
Taxrate = 26.83% (2.45m / 9.15m)
NOPAT = 53.2m (EBIT 72.7m * (1 - 26.83%))
Current Ratio = 5.66 (Total Current Assets 431.4m / Total Current Liabilities 76.2m)
Debt / Equity = -0.22 (negative equity) (Debt 117.1m / totalStockholderEquity, last quarter -533.7m)
Debt / EBITDA = -1.04 (Net Debt -98.2m / EBITDA 94.2m)
Debt / FCF = 3.67 (negative FCF - burning cash) (Net Debt -98.2m / FCF TTM -26.7m)
Total Stockholder Equity = 246.1m (last fiscal year from totalStockholderEquity)
RoA = 6.05% (Net Income 45.5m / Total Assets 948.1m)
RoE = 18.50% (Net Income TTM 45.5m / Total Stockholder Equity 246.1m)
RoCE = 21.22% (EBIT 72.7m / Capital Employed (Equity 246.1m + L.T.Debt 96.6m))
RoIC = 6.31% (NOPAT 53.2m / Invested Capital 842.7m)
WACC = 21.58% (E(839.4m)/V(956.5m) * Re(22.21%) + D(117.1m)/V(956.5m) * Rd(23.32%) * (1-Tc(0.27)))
Discount Rate = 22.21% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
[DCF] Fair Price = unknown (Cash Flow -26.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=0.52 | Chg30d=+16.85% | Revisions=+0% | GrowthEPS=+0.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=0.69 | Chg30d=-2.90% | Revisions=+0% | GrowthEPS=+32.8% | GrowthRev=+15.4%
[Analyst] Revisions Ratio: +0% (up=0, down=0)